A significant legal challenge has emerged within the American healthcare landscape as three prominent health systems—Mount Sinai, Michigan Medicine, and the University of Kansas Health System—have initiated litigation against CVS Health. At the heart of this dispute is the 340B Drug Pricing Program, a federal initiative designed to help safety-net hospitals stretch scarce federal resources to reach more patients and provide comprehensive services. The plaintiffs allege that CVS Health, through its pharmacy benefit manager (PBM) subsidiary, engaged in a practice known as “spread pricing” that resulted in the diversion of approximately $250 million in savings intended for these medical institutions between 2020 and 2025.
This high-stakes litigation underscores growing tensions between major health systems and PBMs over the transparency of drug pricing and the management of pharmaceutical benefits. As the Editor of the Health section at World Today Journal, I have covered numerous shifts in healthcare policy, but the mechanics of the 340B program remain among the most complex and vital components of hospital operations. The outcome of this case could have far-reaching implications for how hospitals across the United States navigate their pharmacy contracts and ensure that federal savings directly benefit the patient populations they serve.
Understanding the 340B Drug Pricing Program
To grasp the significance of this lawsuit, it is essential to understand the intent of the 340B program. Created by Congress under the Veterans Health Care Act of 1992, the program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations at significantly reduced prices. According to the Health Resources and Services Administration (HRSA), which oversees the program, these savings allow hospitals to expand access to care, fund specialized clinics, and provide services to uninsured or underinsured patients.
However, the operational complexity of managing these medications often requires hospitals to contract with PBMs to process claims and manage pharmacy networks. The plaintiffs in this case argue that the PBM model utilized by CVS Health has effectively siphoned off the financial benefits that the 340B program is statutorily required to provide to hospitals. By allegedly keeping the difference between what the PBM charges a health plan for a drug and what it pays the pharmacy—a practice known as spread pricing—the PBM is accused of eroding the intended financial relief meant for these medical centers.
The Allegations: Spread Pricing and Financial Diversion
The core of the legal complaint centers on the financial mechanics between 2020 and 2025. Spread pricing is a contentious practice in the pharmacy benefit industry. When a PBM charges an insurer more for a drug than it reimburses the pharmacy, it retains the “spread” as revenue. The health systems involved in this suit contend that by applying this model to 340B-eligible claims, CVS Health effectively bypassed the cost-saving protections the federal government established for these institutions.
The figure of $250 million, cited in court documents, represents the scale of the savings that the health systems claim were diverted rather than passed on to the hospitals. Financial transparency in pharmaceutical supply chains has been a frequent subject of scrutiny by the Federal Trade Commission (FTC), which has recently increased its oversight into how PBM business practices affect the cost and availability of medications. While the legal proceedings are in the early stages, the allegations highlight a fundamental conflict of interest that critics have long associated with the PBM industry: the potential for intermediaries to profit at the expense of both patients and the providers who care for them.
Implications for Healthcare Policy and Patient Care
For patients, the ripple effects of this litigation are significant. When hospitals lose the financial cushion provided by 340B savings, their ability to subsidize costly services—such as oncology care, infusion centers, and community outreach programs—may be jeopardized. As a physician who has witnessed the impact of drug costs on patient adherence, I view the integrity of these programs as a cornerstone of equitable public health.
The health systems involved—Mount Sinai, Michigan Medicine, and the University of Kansas Health System—represent a diverse cross-section of academic medical centers, each playing a critical role in their respective regional healthcare ecosystems. Their decision to take collective legal action reflects a broader frustration among healthcare providers regarding the opacity of PBM contracts. If the court finds that these savings were improperly diverted, it could necessitate a massive restructuring of how PBMs interact with 340B-eligible entities, potentially forcing greater transparency in drug reimbursement models.
Looking Ahead: The Path Through the Courts
As this case proceeds, the legal community and healthcare stakeholders will be watching closely for how the court interprets the interplay between private contractual agreements and the federal mandates of the 340B program. The judiciary will be tasked with determining whether the PBM’s pricing strategies violated the spirit and legal requirements of the 340B statute during the five-year period in question.
Currently, there is no set date for a final resolution, and the legal teams for both sides are in the process of discovery and motion practice. We will continue to track official court filings and any subsequent statements from the involved parties. For those interested in the ongoing oversight of the 340B program, the HRSA Office of Pharmacy Affairs provides the most current regulatory updates and guidance regarding program compliance and policy changes.
We invite our readers to share their perspectives on this development. Does the current PBM model require further regulation to protect hospital savings, or are these disputes better handled through private contract renegotiation? Please join the conversation in the comments section below or share this article to help inform your community about the complexities of our pharmaceutical supply chain.